FDA rejects Aricept skin patch for Alzheimer's disease

04/25/2011 | Pharmaceutical Business Review Online · MedCityNews.com

The FDA declined to approve Eisai and Teikoku Pharma's weekly transdermal-patch version of Aricept, a treatment for Alzheimer's disease. The companies will review the agency's complete-response letter to determine their next step, Eisai said.

View Full Article in:

Pharmaceutical Business Review Online · MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC